Comparative Pharmacology
Head-to-head clinical analysis: ADQUEY versus JAIMIESS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADQUEY versus JAIMIESS.
ADQUEY vs JAIMIESS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ADQUEY (aducanumab) is a human monoclonal antibody that selectively targets aggregated forms of amyloid beta (Aβ), including soluble oligomers and insoluble fibrils, reducing Aβ plaques in the brain. The exact mechanism linking Aβ reduction to clinical improvement is not fully established.
Norepinephrine and dopamine reuptake inhibitor; also weakly inhibits serotonin reuptake. Enhances synaptic concentrations of norepinephrine and dopamine, particularly in prefrontal cortex.
400 mg orally once daily with food.
100 mg orally once daily with food.
None Documented
None Documented
Terminal half-life 12-15 hours; prolonged in renal impairment (up to 30 hours in CrCl <30 mL/min)
Terminal elimination half-life is approximately 12-15 hours in healthy adults; prolonged in renal impairment (up to 30 hours in severe impairment).
Renal: 70-80% unchanged; Fecal: 5-10% as metabolites; Biliary: minimal (<2%)
Primarily renal excretion as unchanged drug (approximately 70%) with the remainder as inactive metabolites; less than 10% excreted in feces.
Category C
Category C
Oral Contraceptive
Oral Contraceptive, Combined